Download PDF
Thromb Haemost 1998; 80(01): 24-27
DOI: 10.1055/s-0037-1615132
Review Articles
Schattauer GmbH

Factor XI and Protection of the Fibrin Clot against Lysis – a Role for the Intrinsic Pathway of Coagulation in Fibrinolysis

Bonno N. Bouma
1   From the Department of Haematology, University Hospital, Utrecht, The Netherlands
,
Peter A. Kr. von dem Borne
1   From the Department of Haematology, University Hospital, Utrecht, The Netherlands
,
Joost C. M. Meijers
1   From the Department of Haematology, University Hospital, Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 22 January 1998

Accepted 31 March 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Introducation

Blood coagulation is an important mechanism that maintains the integrity of the vascular system to prevent blood loss after injury. The conceptions on the working mechanism of coagulation are based on the waterfall or cascade model, which was already proposed more than 30 years ago, independently by Davie and Ratnoff (1) and MacFarlane (2). Blood coagulation was viewed as a series of linked proteolytic reactions in which zymogens are converted into serine proteases, ultimately leading to the formation of thrombin, which converts soluble fibrinogen into insoluble fibrin. Coagulation was thought to proceed via two pathways, an extrinsic and an intrinsic pathway. Activation of the extrinsic pathway of coagulation occurs by the exposition of tissue factor at the site of injury (3) whereas the intrinsic system is activated after exposure of plasma to an activating surface. Although the in vivo activating surface is unknown, the contact system was believed to play a role in the initiation of the intrinsic pathway. This system consists of factor XII, prekallikrein, high molecular weight kininogen and factor XI. The physiological relevance of the contact system is unclear, since a deficiency of factor XII, prekallikrein or high molecular weight kininogen does not result in a bleeding disorder. In contrast, patients deficient in factor XI, most common among Ashkenazi Jews, do suffer from variable bleeding abnormalities especially from tissues with high local fibrinolytic activity (urinary tract, nose, oral cavity, tonsils) (4, 5). This suggested there was an alternative route for the activation of factor XI, and recently such a route was described (6, 7). Thrombin was found to activate factor XI, even in the absence of a negatively charged surface (6-11), and factor XI was shown to play a role in the protection of the fibrin clot against lysis (9). In plasma the possibility cannot be excluded that the activation of factor XI by thrombin takes place via an intermediary component. Recently, it was shown that meizothrombin was capable of activating factor XI (12).

 

  • References

  • 1 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting.. Science 1964; 145: 1310-2.
    CrossrefPubMedGoogle Scholar
  • 2 MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier.. Nature 1964; 202: 498-9.
    CrossrefPubMedGoogle Scholar
  • 3 Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a “Prima Ballerina”.. Thromb Haemost 1995; 74: 7-17.
    PubMedGoogle Scholar
  • 4 Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel.. N Engl J Med 1991; 325: 153-8.
    CrossrefPubMedGoogle Scholar
  • 5 Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe factor XI deficiency without plasma replacement.. Blood Coagul Fibrinol 1991; 3: 465-8.
    PubMedGoogle Scholar
  • 6 Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces.. J Biol Chem 1991; 266: 7353-8.
    PubMedGoogle Scholar
  • 7 Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation.. Science 1991; 253: 909-12.
    CrossrefPubMedGoogle Scholar
  • 8 Von dem Borne PAK, Koppelman SJ, Bouma BN, Meijers JCM. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen.. Thromb Haemost 1994; 72: 397-402.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 von dem Borne PAK, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.. Blood 1995; 86: 3035-42.
    PubMedGoogle Scholar
  • 10 Cawthern KM, van’t Veer C, Lock JB, Branda RF, Mann KG. Regulation of thrombin generation by tissue factor, factor VIIIa and factor XIa in a whole blood model.. Blood 1996; 88: 520a (Abstr.).
    PubMedGoogle Scholar
  • 11 Oliver JA, Monroe DM, Hoffman M, Roberts HR. Factor XI increases thrombin generation in a cell-based system in the absence of factor XII.. Blood 1996; 88: 469a (Abstr.).
    PubMedGoogle Scholar
  • 12 von dem Borne PAK, Mosnier LO, Tans G, Meijers JCM, Bouma BN. Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine.. Thromb Haemost 1997; 78: 834-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Osterud B, Rapaport S. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.. Proc Natl Acad Sci USA 1977; 74: 5260-4.
    CrossrefPubMedGoogle Scholar
  • 14 Marlar RA, Kleiss AJ, Griffin JH. An alternative pathway of human blood coagulation.. Blood 1982; 60: 1353-8.
    PubMedGoogle Scholar
  • 15 Broze GJ. The role of tissue factor pathway inhibitor in a revised coagulation cascade.. Semin Hematol 1992; 29: 159-69.
    PubMedGoogle Scholar
  • 16 Rand MD, Lock JB, van ’t Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood.. Blood 1996; 88: 3422-45.
    PubMedGoogle Scholar
  • 17 Ichinose A. The physiology and biochemistry of factor XIII.. In: Haemostasis and Thrombosis.. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Edinburgh: Churchill Livingstone; 1994. pp 531-46.
    Google Scholar
  • 18 Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin.. J Biol Chem 1986; 261: 3486-90.
    PubMedGoogle Scholar
  • 19 Gurewich V, Pannell R. Inactivation of single-chain urokinase (Pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.. Blood 1987; 69: 769-72.
    PubMedGoogle Scholar
  • 20 Lijnen HR, van Hoef B, Collen D. Activation with plasmin of two-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment of thrombin.. Eur J Bioch 1987; 169: 359-64.
    CrossrefPubMedGoogle Scholar
  • 21 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor.. J Biol Chem 1995; 270: 14477-84.
    CrossrefPubMedGoogle Scholar
  • 22 Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma.. Biochemistry 1995; 34: 5811-6.
    CrossrefPubMedGoogle Scholar
  • 23 Hendriks D, Scharpe S, Van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N.. J Clin Chem Clin Biochem 1989; 27: 277-85.
    PubMedGoogle Scholar
  • 24 Wang W, Hendriks D, Scharpe S. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen.. J Biol Chem 1994; 269: 15937-44.
    PubMedGoogle Scholar
  • 25 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system.. J Clin Invest 1995; 96: 2534-8.
    CrossrefPubMedGoogle Scholar
  • 26 von dem Borne PAK, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a TAFI (thrombin activatable fibrinolysis inhibitor) dependent inhibition of fibrinolysis.. J Clin Invest 1997; 99: 2323-7.
    CrossrefPubMedGoogle Scholar
  • 27 Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity – a role in clot lysis in vivo.. Circulation 1996; 93: 1328-30.
    CrossrefPubMedGoogle Scholar
  • 28 Greenberg CS, Miraglia CC, Rickles FR, Shuman MA. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.. J Clin Invest 1985; 75: 1463-70.
    CrossrefPubMedGoogle Scholar
  • 29 Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, Abbink JJ, Strack van Schijndel RJM, Felt-Bersma RJF, Thijs LG, Hack CE. Quantification of plasma factor XII-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis.. Blood 1988; 72: 1841-8.
    PubMedGoogle Scholar
  • 30 Pixley RA, dela Cadena RA, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor FB. Activation of the contact system in lethal hypotensive bacteremia in a baboon model.. Am J Path 1992; 140: 897-906.
    PubMedGoogle Scholar
  • 31 Van der Linden PWG, Hack CE, Eerenberg AJM, Struyvenberg A, van der Zwan JK. Activation of the contact system in insect-sting anaphylaxis: association with the development of angioedema and shock.. Blood 1993; 82: 1732-9.
    PubMedGoogle Scholar
  • 32 Abbink JJ, Kamp AM, Nuijens JH, Eerenberg AJM, Swaak AJF, Hack CE. Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.. Ann Rheum Dis 1992; 51: 123-8.
    CrossrefPubMedGoogle Scholar
  • 33 Colman RW. Surface-mediated defense reactions. The plasma contact activation system.. J Clin Invest 1984; 73: 1249-53.
    CrossrefPubMedGoogle Scholar
  • 34 Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma.. Blood 1987; 70: 1-15.
    PubMedGoogle Scholar
  • 35 Bajzar L, Nesheim M, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent.. Blood 1996; 88: 2093-100.
    PubMedGoogle Scholar
  • 36 De Fouw NJ, Haverkate F, Bertina RM. Protein C and fibrinolysis: a link between coagulation and fibrinolysis.. Adv Exp Med Biol 1990; 281: 235-43.
    PubMedGoogle Scholar
  • 37 Bajzar L, Nesheim ME. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation.. J Biol Chem 1993; 268: 8608-16.
    PubMedGoogle Scholar
  • 38 Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor.. Blood 1986; 68: 1218-23.
    PubMedGoogle Scholar
  • 39 Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C.. Nature 1994; 369: 64-7.
    CrossrefPubMedGoogle Scholar
  • 40 Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden.. J Biol Chem 1996; 271: 22949-52.
    CrossrefPubMedGoogle Scholar
  • 41 Griffin JH. Blood coagulation – the thrombin paradox.. Nature 1995; 378: 337-8.
    CrossrefPubMedGoogle Scholar
  • 42 Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Anti-thrombotic effects of thrombin-induced activation of endogenous protein C in primates.. J Clin Invest 1993; 92: 2003-12.
    CrossrefPubMedGoogle Scholar
  • 43 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation.. Blood 1987; 70: 343-50.
    PubMedGoogle Scholar
  • 44 Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, ten Cate H, Kestin AS, Brettler DB, Rosenberg RD. Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.. Blood 1992; 79: 2039-47.
    PubMedGoogle Scholar
  • 45 Bajzar L, Morser J, Nesheim ME. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex.. J Biol Chem 1996; 271: 16603-8.
    CrossrefPubMedGoogle Scholar
  • 46 Broze GJ, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.. Blood 1996; 88: 3815-23.
    PubMedGoogle Scholar
  • 47 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B.. J Biol Chem 1997; 272: 14477-82.
    CrossrefPubMedGoogle Scholar
  • 48 Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A.. Br J Haematol 1984; 58: 741-53.
    CrossrefPubMedGoogle Scholar
  • 49 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.. Am J Path 1989; 134: 1087-97.
    PubMedGoogle Scholar
  • 50 Walsh PN, Rizza CR, Matthews JM, Eipe J, Kernoff PBA, Coles MD, Bloom AL, Kaufman JM, Beck P, Hanan CM, Biggs R. Epsilon-amino-caproic acid therapy for dental extractions in haemophilia and christmas disease: a double blind controlled trial.. Br J Haematol 1971; 20: 463-75.
    CrossrefPubMedGoogle Scholar
  • 51 Minnema MC, Friederich PW, Levi M, von dem Borne PAK, Mosnier LO, Meijers JCM, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of jugular vein thrombolysis by neutralization of factor XI: in vivo evidence for a role of factor XI as antifibrinolytic factor.. J Clin Invest 1998; 101: 10-4.
    CrossrefPubMedGoogle Scholar